Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 258

Sort by

Sort Order Select

Journal Articles

BLAST: A Globally Applicable and Molecularly Versatile Survival Model for Chronic Myelomonocytic Leukemia

Blood blood.2024027170.

https://doi.org/10.1182/blood.2024027170

Published: 2025

Includes: Supplemental data

Journal Articles

Role of allo-HCT in "nonclassical" MPNs and MDS/MPNs: recommendations from the PH&G Committee and the CMWP of the EBMT

Nicola Polverelli, Juan Carlos Hernandez-Boluda, Francesco Onida, Carmelo Gurnari, Kavita Raj, Tomasz Czerw, Michelle Kenyon, Marie Robin, Katja Sockel, Annalisa Ruggeri, Isabel Sánchez-Ortega, Daniel A. Arber, Luca Arcaini, Fernando Barroso Duarte, Giorgia Battipaglia, Yves Chalandon, Fabio Ciceri, Nicholas C.P. Cross, Joanna Drozd-Sokolowska, Vaneuza Araújo Moreira Funke, Nico Gagelmann, Naseema Gangat, Jason Gotlib, Paola Guglielmelli, Claire N. Harrison, Gabriela S Hobbs, Tania Jain, Joseph D. Khoury, Jean-Jacques Kiladjian, Nicolaus Kröger, Luca Malcovati, Massimo Martino, Ruben Mesa, Attilio Orazi, Eric Padron, Francesca Palandri, Francesco Passamonti, Mrinal M. Patnaik, Naveen Pemmaraju, Deepti H. Radia, Andreas Reiter, Domenico Russo, Christof Scheid, Ayalew Tefferi, Alessandro M. Vannucchi, Daniel Howard Wiseman, Ibrahim Yakoub-Agha, Donal P McLornan

Blood blood.2024028000.

https://doi.org/10.1182/blood.2024028000

Published: 2025

Includes: Supplemental data

Journal Articles

High-dose IV ascorbic acid therapy for patients with CCUS with TET2 mutations

Zhuoer Xie, Jenna Fernandez, Terra Lasho, Christy Finke, Michelle Amundson, Kristen B. McCullough, Betsy R. LaPlant, Abhishek A. Mangaonkar, Naseema Gangat, Kaaren K. Reichard, Michelle Elliott, Thomas E. Witzig, Mrinal M. Patnaik

Blood (2024) 144 (23): 2456–2461.

https://doi.org/10.1182/blood.2024024962

Published: 2024

Includes: Supplemental data

Journal Articles

Venetoclax in Combination with Hypomethylating Agent (HMA) Compared to HMA Alone Improves Response but Not Survival in TP53- mutated High-Risk Myelodysplastic Syndrome: Real-World Mayo Clinic Series

Talha Badar, Kashish J. Shah, Mobachir El Kettani, James M. Foran, Mohamed A. Kharfan-Dabaja, Hemant S. Murthy, Naseema Gangat, Aref Al-Kali, Mithun V Shah, Hassan B Alkhateeb, Antoine N. Saliba, William J. Hogan, Cecilia Y. Arana Yi, Lisa Sproat, Jeanne Palmer, Mark R. Litzow, Mrinal M. Patnaik

Blood (2024) 144 (Supplement 1): 1823.

https://doi.org/10.1182/blood-2024-203825

Published: 2024

Journal Articles

Autoimmune or Inflammatory Diseases in 1,968 Consecutive Patients with Polycythemia Vera and Essential Thrombocythemia: Impact on Disease Outcome and Co-Morbidities

Fnu Aperna, Moazah Iftikhar, Masooma S Rana, Animesh D. Pardanani, Paola Guglielmelli, Alessandro Maria Vannucchi, Naseema Gangat, Ayalew Tefferi, Giuseppe Gaetano Loscocco

Blood (2024) 144 (Supplement 1): 3171.

https://doi.org/10.1182/blood-2024-203394

Published: 2024

Journal Articles

Prognostic Impact of the Number of TET2 Mutations in Myelodysplastic and Myeloproliferative Chronic Myelomonocytic Leukemia (CMML)

Blood (2024) 144 (Supplement 1): 1820.

https://doi.org/10.1182/blood-2024-209193

Published: 2024

Journal Articles

Revised Mayo Molecular Risk Model for Chronic Myelomonocytic Leukemia (MMM version 2.0): A Combined Clinical, Cytogenetic, and Mutational Platform

Ayalew Tefferi, Saubia Fathima, Ali Khalid Alsugair, Clifford M. Csizmar, Mark Gurney, Terra L. Lasho, Christy Finke, Abhishek A. Mangaonkar, Aref Al-Kali, Hassan B Alkhateeb, Kaaren K. Reichard, Animesh D. Pardanani, Naseema Gangat, Mrinal M. Patnaik

Blood (2024) 144 (Supplement 1): 1827.

https://doi.org/10.1182/blood-2024-207736

Published: 2024

Journal Articles

A Phase 1b Study of DISC-0974, an Anti-Hemojuvelin Antibody, in Patients with Myelofibrosis and Anemia

Naseema Gangat, James M. Foran, Anna B. Halpern, Raajit Rampal, Prithviraj Bose, Elizabeth O. Hexner, Moshe Talpaz, Laura C. Michaelis, Prioty Islam, Ronan T. Swords, Sima Bhatt, Akshay Buch, Olivia Pelletier, Will Savage, Ayalew Tefferi

Blood (2024) 144 (Supplement 1): 657.

https://doi.org/10.1182/blood-2024-203719

Published: 2024

Journal Articles

Prevalence and Clinical Features of Non-Myeloid Neoplasms in Patients with DDX41 Mutant Germline Predisposition Syndrome

Yael Kusne, Talha Badar, Terra L. Lasho, Ludovica Marando, Abhishek A. Mangaonkar, Christy Finke, James M. Foran, Aref Al-Kali, Hassan B Alkhateeb, Naseema Gangat, Jeanne Palmer, David Viswanatha, Mark R. Litzow, Timothy Chlon, Alejandro Ferrer, Mrinal M. Patnaik

Blood (2024) 144 (Supplement 1): 440.

https://doi.org/10.1182/blood-2024-203879

Published: 2024

Journal Articles

Predictors of Relapse and Post-Relapse Outcomes in Patients with Newly-Diagnosed Acute Myeloid Leukemia Treated with Venetoclax + Hypomethylating Agent

Blood (2024) 144 (Supplement 1): 2852.

https://doi.org/10.1182/blood-2024-209015

Published: 2024

Journal Articles

TP53 Mutations in Myeloproliferative Neoplasms: Context-Dependent Evaluation of Prognostic Relevance

Blood (2024) 144 (Supplement 1): 244.

https://doi.org/10.1182/blood-2024-210251

Published: 2024

Journal Articles

Pacritinib Therapy for JAK2 Inhibitor-Naïve or -Experienced Patients with Myelofibrosis: Mayo Clinic Series of 60 Consecutive Patients Treated Outside of Clinical Trials

Maymona Abdelmagid, Jeanne Palmer, Aref Al-Kali, Mehrdad Hefazi, James M. Foran, Kebede Begna, Cecilia Y. Arana Yi, Animesh D. Pardanani, Naseema Gangat, Ayalew Tefferi

Blood (2024) 144 (Supplement 1): 1798.

https://doi.org/10.1182/blood-2024-198757

Published: 2024

Journal Articles

The Mutational Landscape of Polycythemia Vera and Its Phenotypic and Prognostic Correlates

Masooma S Rana, Moazah Iftikhar, Yamna Jadoon, Maymona Abdelmagid, David Viswanatha, Rong He, Kaaren K. Reichard, Animesh D. Pardanani, Naseema Gangat, Ayalew Tefferi

Blood (2024) 144 (Supplement 1): 1797.

https://doi.org/10.1182/blood-2024-193119

Published: 2024

Journal Articles

Cytogenetic Abnormalities in Polycythemia Vera: Phenotypic Correlates and Prognostic Relevance in 669 Informative Cases

Moazah Iftikhar, Masooma S Rana, Yamna Jadoon, Maymona Abdelmagid, Kaaren K. Reichard, Cinthya Zepeda Mendoza, Animesh D. Pardanani, Ayalew Tefferi, Naseema Gangat

Blood (2024) 144 (Supplement 1): 3176.

https://doi.org/10.1182/blood-2024-193120

Published: 2024

Journal Articles

Clinical Characteristics of Myeloproliferative Neoplasms in Patients with DDX41 MT Germline Predisposition Syndrome

Blood (2024) 144 (Supplement 1): 3183.

https://doi.org/10.1182/blood-2024-202406

Published: 2024

Journal Articles

Targeting Aberrant DLK1 Re-Expression in ASXL1 -Mutant Chronic Myelomonocytic Leukemia with BRD4 / p300-Directed Epigenetic Small Molecule Therapy

Terra L. Lasho, Jenna A. Fernandez, Jeong-Heon Lee, Linh D. Pham, Huihuang Yan, Christy Finke, Abhishek A. Mangaonkar, Aref Al-Kali, Naseema Gangat, Joseph Collard, Claes Wahlestedt, Mrinal M. Patnaik, Moritz Binder

Blood (2024) 144 (Supplement 1): 3197.

https://doi.org/10.1182/blood-2024-204070

Published: 2024

Journal Articles

Thrombosis Risk Assessment in Polycythemia Vera (TRAP): A 4,636-Patient-Year Analysis of Arterial and Venous Thrombosis in Low-Risk Patients

Naseema Gangat, Giuseppe Gaetano Loscocco, Patricia Carey, Priyansh Faldu, Moazah Iftikhar, Masooma S Rana, Yamna Jadoon, Animesh D. Pardanani, Natasha Szuber, Alessandra Carobbio, Tiziano Barbui, Alessandro Maria Vannucchi, Ayalew Tefferi, Paola Guglielmelli

Blood (2024) 144 (Supplement 1): 3185.

https://doi.org/10.1182/blood-2024-204138

Published: 2024

Journal Articles

DNMT3A Mutant Clonal Hematopoiesis in Vexas Syndrome Epigenetically Potentiates IL-13 and IL-15 Inflammatory Pathways and Is Associated with Increased Mortality

Blood (2024) 144 (Supplement 1): 2686.

https://doi.org/10.1182/blood-2024-204334

Published: 2024

Journal Articles

Outcome of Splenectomy in JAK2 Inhibitor Treated Patients with Myelofibrosis: A Mayo Clinic Experience in 34 Consecutive Cases

Patricia Carey, Animesh D. Pardanani, Patrick Starlinger, Ayalew Tefferi, Naseema Gangat

Blood (2024) 144 (Supplement 1): 6662.

https://doi.org/10.1182/blood-2024-199246

Published: 2024

Journal Articles

TP53 mutations and Complex Karyotype in Newly-Diagnosed Blast/Accelerated Phase MPN Are Associated with Ephemeral Response to Treatment with Venetoclax + HMA and Poor Survival

Blood (2024) 144 (Supplement 1): 6657.

https://doi.org/10.1182/blood-2024-193917

Published: 2024

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

BLAST: A Globally Applicable and Molecularly Versatile Survival Model for Chronic Myelomonocytic Leukemia

Role of allo-HCT in "nonclassical" MPNs and MDS/MPNs: recommendations from the PH&G Committee and the CMWP of the EBMT

High-dose IV ascorbic acid therapy for patients with CCUS with TET2 mutations

Venetoclax in Combination with Hypomethylating Agent (HMA) Compared to HMA Alone Improves Response but Not Survival in TP53- mutated High-Risk Myelodysplastic Syndrome: Real-World Mayo Clinic Series

Autoimmune or Inflammatory Diseases in 1,968 Consecutive Patients with Polycythemia Vera and Essential Thrombocythemia: Impact on Disease Outcome and Co-Morbidities

Prognostic Impact of the Number of TET2 Mutations in Myelodysplastic and Myeloproliferative Chronic Myelomonocytic Leukemia (CMML)

Revised Mayo Molecular Risk Model for Chronic Myelomonocytic Leukemia (MMM version 2.0): A Combined Clinical, Cytogenetic, and Mutational Platform

A Phase 1b Study of DISC-0974, an Anti-Hemojuvelin Antibody, in Patients with Myelofibrosis and Anemia

Prevalence and Clinical Features of Non-Myeloid Neoplasms in Patients with DDX41 Mutant Germline Predisposition Syndrome

Predictors of Relapse and Post-Relapse Outcomes in Patients with Newly-Diagnosed Acute Myeloid Leukemia Treated with Venetoclax + Hypomethylating Agent

TP53 Mutations in Myeloproliferative Neoplasms: Context-Dependent Evaluation of Prognostic Relevance

Pacritinib Therapy for JAK2 Inhibitor-Naïve or -Experienced Patients with Myelofibrosis: Mayo Clinic Series of 60 Consecutive Patients Treated Outside of Clinical Trials

The Mutational Landscape of Polycythemia Vera and Its Phenotypic and Prognostic Correlates

Cytogenetic Abnormalities in Polycythemia Vera: Phenotypic Correlates and Prognostic Relevance in 669 Informative Cases

Clinical Characteristics of Myeloproliferative Neoplasms in Patients with DDX41 MT Germline Predisposition Syndrome

Targeting Aberrant DLK1 Re-Expression in ASXL1 -Mutant Chronic Myelomonocytic Leukemia with BRD4 / p300-Directed Epigenetic Small Molecule Therapy

Thrombosis Risk Assessment in Polycythemia Vera (TRAP): A 4,636-Patient-Year Analysis of Arterial and Venous Thrombosis in Low-Risk Patients

DNMT3A Mutant Clonal Hematopoiesis in Vexas Syndrome Epigenetically Potentiates IL-13 and IL-15 Inflammatory Pathways and Is Associated with Increased Mortality

Outcome of Splenectomy in JAK2 Inhibitor Treated Patients with Myelofibrosis: A Mayo Clinic Experience in 34 Consecutive Cases

TP53 mutations and Complex Karyotype in Newly-Diagnosed Blast/Accelerated Phase MPN Are Associated with Ephemeral Response to Treatment with Venetoclax + HMA and Poor Survival

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only